3 min
TULIP 2: Efficacy and Safety of Anifrolumab in Patients ARD Podcast
-
- Medicine
TULIP 2: Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial.
In this second phase 3 trial, the primary endpoint, BICLA, was achieved, and anifrolumab was superior to placebo for multiple secondary efficacy endpoints, including SRI(4), skin disease, and oral corticosteroid tapering.
TULIP 2: Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial.
In this second phase 3 trial, the primary endpoint, BICLA, was achieved, and anifrolumab was superior to placebo for multiple secondary efficacy endpoints, including SRI(4), skin disease, and oral corticosteroid tapering.
3 min